Dexycu FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved February 9, 2018)
Brand name: Dexycu
Generic name: dexamethasone
Dosage form: Intraocular Suspension
Company: EyePoint Pharmaceuticals, Inc.
Treatment for: Postoperative Ocular Inflammation
Dexycu (dexamethasone) is a long-acting, injectable corticosteroid formulation administered intraocularly into the posterior chamber of the eye for the treatment of postoperative inflammation associated with cataract surgery.
Development timeline for Dexycu
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
